BLOOD 2023: Acalabrutinib for Chronic Lymphocytic Leukemia Not Linked to Increased Cardiac Failure Risk
Safety data from clinical trials and global database used to assess exposure-adjusted incidence rates
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.